Highly metastatic prostate cancer cells flowing through a microfluidic channel form plasma membrane blebs: they form 27% more than normal cells and have a lower stiffness (about 50%). Hypo-osmotic stress assays (with osmolarity) show 22% more blebbing of highly metastatic than moderately metastatic and 30% more than normal cells. Plasma membrane blebbing is known to provide important metastatic capabilities to cancer cells by aiding cell detachment from the primary tumor site and increasing cell deformability to promote cell migration through the extracellular matrix. Increased blebbing was attributed by others to decreased phosphorylated ezrin, radixin, and moesin (ERM) (p-ERM) protein expression—p-ERMs bind the plasma membrane to the actin cortex and reduced p-ERM expression can weaken membrane-cortex attachment. Myosin II also influences blebbing as myosin’s natural contraction generates tension in the actin cortex. This increases cellular hydrostatic pressure, causes cortex rupture, cytoplasm flow out of the cortex, and hence blebbing. Highly metastatic cells are surprisingly found to express similar ezrin and myosin II levels but higher moesin levels in comparison with lowly metastatic or normal cells—suggesting that their levels, contrary to the literature [G. Charras and E. Paluch, Nat. Rev. Mol. Cell Biol. 9(9), 730–736 (2008); J.-Y. Tinevez, U. Schulze, G. Salbreux, J. Roensch, J.-F. Joanny, and E. Paluch, Proc. Natl. Acad. Sci. U.S.A. 106(44), 18581–18586 (2009); M. Bergert, S. D. Chandradoss, R. A. Desai, and E. Paluch, Proc. Natl. Acad. Sci. U.S.A. 109(36), 14434–14439 (2012); E. K. Paluch and E. Raz: Curr. Opin. Cell Biol. 25(5), 582–590 (2013)], are not important in metastatic prostate cell blebbing. Our results show that reduced F-actin is primarily responsible for increased blebbing in these metastatic cells. Blebbing can thus serve as a simple prognostic marker for the highly incident and lethal metastatic prostate cancer.
Skip Nav Destination
Article navigation
Research Article|
May 21 2019
Enhanced blebbing as a marker for metastatic prostate cancer
Zeina S. Khan;
Zeina S. Khan
Department of Mechanical Engineering, Texas Tech University
, Lubbock, Texas 79409, USA
Search for other works by this author on:
Julianna M. Santos;
Julianna M. Santos
Department of Mechanical Engineering, Texas Tech University
, Lubbock, Texas 79409, USA
Search for other works by this author on:
Neil G. Vaz
;
Neil G. Vaz
Department of Mechanical Engineering, Texas Tech University
, Lubbock, Texas 79409, USA
Search for other works by this author on:
Fazle Hussain
Fazle Hussain
a)
Department of Mechanical Engineering, Texas Tech University
, Lubbock, Texas 79409, USA
Search for other works by this author on:
a)
Electronic mail: [email protected]
Biomicrofluidics 13, 034110 (2019)
Article history
Received:
December 11 2018
Accepted:
April 22 2019
Citation
Zeina S. Khan, Julianna M. Santos, Neil G. Vaz, Fazle Hussain; Enhanced blebbing as a marker for metastatic prostate cancer. Biomicrofluidics 1 May 2019; 13 (3): 034110. https://doi.org/10.1063/1.5085346
Download citation file:
Pay-Per-View Access
$40.00
Sign In
You could not be signed in. Please check your credentials and make sure you have an active account and try again.
Citing articles via
Processing and inspection of high-pressure microfluidics systems: A review
Jiangyi Song, Shaoxin Meng, et al.
Design of 3D printed chip to improve sensitivity of platelet adhesion through reinjection: Effect of alcohol consumption on platelet adhesion
Haebeen Kim, Hae-Ryoun Park, et al.
Impact of dcEF on microRNA profiles in glioblastoma and exosomes using a novel microfluidic bioreactor
Hsieh-Fu Tsai, Amy Q. Shen
Related Content
Rapid and automatic phenotyping of cells through their annexin-mediated enforced blebbing response
AIP Advances (March 2024)
Cytotoxicity effect of lysates from Acanthamoeba spp. against MCF 7 cell lines
AIP Conf. Proc. (June 2023)
Aggressive prostate cancer cell nuclei have reduced stiffness
Biomicrofluidics (January 2018)
How cytoskeletal crosstalk makes cells move: Bridging cell-free and cell studies
Biophysics Rev. (June 2024)
Phenotyping of rare circulating cells in the blood of non-metastatic breast cancer patients using microfluidic Labyrinth technology
Biomicrofluidics (December 2022)